About
Dr. Ian Hardcastle is a researcher at Newcastle University, specializing in Cancer Biology, Protein-Protein Interaction Inhibition, and Medicinal Chemistry. His work focuses on designing small molecule inhibitors targeting kinases like MDM2-p53, ERK5, and CDK2 for anticancer therapeutics.
- Key Research Areas: Kinase Inhibition, Drug Design, Cancer Signaling
- Notable Projects: Development of ASTX295 (2024), ERK5 Inhibitors, and Bromodomain Probes (2022)
Article Trends
His publications emphasize structure-based drug design, pharmacokinetic optimization, and targeting cancer-specific pathways (MDM2-p53, ERK5, CDK2). Techniques include fragment-based screening (FragLites), covalent inhibition, and enantioselective synthesis.
Collaborations
- Collaborated with Professor Jane Endicott, Dr. Celine Cano, and Emeritus Professor Bernard Golding on multiple projects
0Publications listed